39640-51-2

Usage

InChI:InChI=1/C9H11NO2/c1-3-12-9(11)8-6-4-5-7(2)10-8/h4-6H,3H2,1-2H3

Upstream product

• 934-60-1 6-methyl-2-pyridinecarboxylic acid 
• 64-17-5 ethanol 
• 1197-10-0 6-(hydroxymethyl)pyridine-2-carboxylic acid 
• 108-48-5 2,6-dimethylpyridine 

Downstream Products

• 476472-02-3 1-(6-methylpyridin-2-yl)-2-(quinolin-4-yl)ethan-1-one 
• 607737-87-1 4-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)quinoline 
• 879486-42-7 2-[4-(3-bromo-phenyl)-1H-pyrazol-3-yl]-6-methylpyridine 
• 97278-44-9 6-bromomethylpyridine-2-carboxylic acid ethylester 
• 150401-96-0 ethyl 3-(6-methylpyridin-2-yl)-3-oxopropanoate 
• 879486-39-2 2-(3-bromo-phenyl)-1-(6-methyl-pyridin-2-yl)ethanone 
• 21908-10-1 ethyl 6-formyl-2-pyridinecarboxylate 
• 868395-53-3 3-(6-methylpyridin-2-yl)-3-oxopropionitrile 
• 109502-67-2 2,3-dimethoxy-6-[(6-methyl-pyridine-2-carbonylhydrazono)-methyl]-benzoic acid 
• 101281-48-5 6-methyl-pyridine-2-carboxylic acid-(4-acetylamino-benzylidenehydrazide) 
• 100867-62-7 6-methyl-pyridine-2-carboxylic acid benzylidenehydrazide 
• 101938-10-7 2-methyl-6-(1-(phenylmethylamino)methyl)pyridine 
• 115153-58-7 6-[(E)-2-(3,4-Dimethoxy-phenyl)-vinyl]-pyridine-2-carboxylic acid ethyl ester 
• 115153-57-6 6-[(E)-2-(2,4-Dichloro-phenyl)-vinyl]-pyridine-2-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5

The present invention relates to novel benzylamide derivatives of formula (I) to processes for the preparation of said compounds; to pharmaceutical compositions comprising said compounds and to said compounds for use in the treatment of pathological conditions or diseases that can improve by inhibition of transforming growth factor-β receptor I (TGFβRI)/ALK5, such as diseases and disorders associated to fibrotic conditions of gastrointestinal system, skin and eyes, to methods for the treatment and/or prevention of said diseases or pathological conditions and to combinations comprising said compounds and further comprising therapeutically effective amounts of other therapeutic agents useful for the treatment of said diseases or pathological conditions.

Pd-containing organopolyoxometalates derived from Dawson polyoxometalate [P2W15V3O62]9-: Lewis acidity and dual site catalysis

Grafting of a palladium complex to the Dawson vanadotungstate polyanion [P2W15V3O62]9- via an organic ligand generates a large family of pincer-type hybrid polyoxometalates. The palladium-POM derivatives have dual catalytic properties. Unlike their parent inorganic polyanions, they catalyze allylations while retaining their oxidant character, which leads to single-pot dual site catalysis. This opens a new route for multicatalytic reactions.

SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION

Pharmaceutical compositions of the invention are presented which comprise substiuted aminothiazoles derivatives. The substiuted aminothiazoles derivatives have a disease-modifying action in the treatment of diseases associated with unregulated cell growth. Such diseases include cancers such as hepatocellular carcinoma, and viral infections from a hepatitis virus.

Theramutein modulators

This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.

THERAMUTEIN MODULATORS

This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.

ARYL SULFONAMIDES

The present invention relates to compounds that modulate various chemokine receptors. These compounds are useful for treating inflammatory and immune diseases.

2-PHENYLPYRIDIN-4-YL DERIVATIVES AS ALK5 INHIBITORS

This invention relates to novel 2-phenylpyridin-4-yl heterocyclyl derivatives which are inhibitors of the transforming growth factor, ("TGF")-? signalling pathway, in particular, the phosphorylation of smad2 or smad3 by the TGF-β type I or activin-like kinase ("ALK")-5 receptor, methods for their preparation and their use in medicine, specifically in the treatment and prevention of a disease state mediated by this pathway.

Studies on the hydrogenation of 6-(hydroxymethyl)pyridine-2-carboxylates and its application to the synthesis of 6-(hydroxymethyl)piperidine-2-carboxylic acid derivatives

The synthesis of the novel amino acid 6-(hydroxymethyl)-2-piperidinecarboxylic acid (1a) and its ethyl ester 1b is reported. In the hydrogenation of 6-(hydroxymethyl)pyridine-2-carboxylates, hydrogenolysis of the alcohol group appeared as an unusual side reaction. Optimization of the reaction conditions allowed us to minimize hydrogenolysis and afforded pure 1.